● pepmg Research Desk · Peer-reviewed evidence review
What the research says about tesofensine
A neutral summary of the peer-reviewed literature on tesofensine, an oral triple monoamine reuptake inhibitor studied for weight reduction, whose pivotal obesity trial later drew a journal Expression of Concern. Research use only.
Limited evidence — Early or small human data, or strong preclinical work. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Tesofensine is an oral triple monoamine reuptake inhibitor (it blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin); it was first tested for neurodegenerative disease, where unintended weight loss was noticed, and was then redeveloped as a candidate anti-obesity drug [1].
- In a phase 2, randomized, placebo-controlled obesity trial, tesofensine plus diet produced a mean weight loss of up to 10.6% at the highest dose versus 2.0% with diet and placebo over 24 weeks [2].
- That pivotal trial later received a journal Expression of Concern, and a separate report described under-reporting of adverse effects; tesofensine is an investigational compound and has not, in this corpus, completed and reported a large confirmatory trial [8][9].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What tesofensine is
Tesofensine (development code NS2330) is described in the literature as a centrally acting inhibitor of the presynaptic reuptake of three monoamine neurotransmitters, noradrenaline, dopamine, and serotonin, and is thought to enhance signaling of all three [1][3]. It was originally developed for neurodegenerative conditions such as Parkinson's and Alzheimer's disease; it was ineffective for those indications, but a notable occurrence of unintended weight loss was observed, which redirected its development toward obesity [1].
The proposed mechanism for weight loss centers on appetite suppression. Preclinical work in mice and rats has reported that tesofensine acts on GABAergic neurons in the lateral hypothalamus, a feeding-related circuit, to reduce food intake [7]. Tesofensine has never been an approved medicine, and material sold by research-chemical vendors is not an approved pharmaceutical product and is offered for laboratory and research use only.
What the human research has measured
Limited evidenceThe central human study is a phase 2, randomized, double-blind, placebo-controlled trial in 203 adults with obesity across five Danish centers, in which participants received an energy-restricted diet plus tesofensine or placebo for 24 weeks. The mean weight loss with diet and placebo was 2.0%; with tesofensine plus diet it was 9.2% and 10.6% at the two higher doses, significantly greater than placebo [2]. A meta-analysis of four earlier randomized trials in Parkinson's or Alzheimer's disease (where weight was not the goal) estimated a placebo-subtracted weight loss of approximately 4% over more than 14 weeks and documented dose-dependent increases in heart rate, up to 6.8 bpm, without a consistent effect on blood pressure [5].
Mechanistic human studies examined how the weight loss arises. In a randomized appetite study, tesofensine produced a dose-dependent increase in a composite satiety score that correlated with weight loss (r = 0.36), though the satiety effect diminished as weight loss progressed [4]; a separate randomized crossover study measured 24-hour energy expenditure and appetite to probe the same question [3]. A small randomized trial (21 adults) of Tesomet, a fixed combination of tesofensine with the beta-blocker metoprolol, in hypothalamic obesity reported an additional mean weight change of -6.3% versus placebo over 24 weeks [6].
All of this is phase 2 or smaller. The trials measured percent weight change and appetite over weeks; a large phase 3 confirmatory obesity trial does not appear as a completed, reported study in this corpus.
What the studies report on safety and adverse events
Limited evidenceIn the phase 2 obesity trial the most common adverse events were dry mouth, nausea, constipation, hard stools, diarrhea, and insomnia [2]. Because tesofensine is a monoamine reuptake inhibitor, its cardiovascular and neuropsychiatric effects have drawn particular attention: reviews and the meta-analysis describe dose-dependent elevations in heart rate and, at the highest dose tested, increases in blood pressure [1][5]. In the small Tesomet trial, tesofensine-related events were mostly mild and included sleep disturbances (Tesomet 50%, placebo 13%), dry mouth (Tesomet 43%, placebo 0%), and headache (Tesomet 36%, placebo 0%), and one participant had a treatment-related serious adverse event of exacerbated pre-existing anxiety [6].
Two publications complicate the safety picture and must be read alongside the efficacy data. The journal that published the pivotal phase 2 obesity trial subsequently issued an Expression of Concern about that trial [8], and a separate report described under-reporting of adverse effects of tesofensine [9]. These are reasons to treat the reported adverse-event tallies as incomplete rather than settled.
None of this is a safety guarantee. The human evidence is limited and early, the pivotal trial carries an Expression of Concern, and material sold by research-chemical vendors is not manufactured to pharmacy standards or evaluated for long-term safety. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence base is characterized as limited. Human data exist and include randomized, placebo-controlled trials showing dose-related weight loss and appetite suppression over weeks [2][4][6], but the body of work is small, largely phase 2, and concentrated in a single development program. "Limited" here reflects both the early stage of the human evidence and specific integrity concerns: the pivotal obesity trial received a journal Expression of Concern [8], and adverse-event reporting was separately criticized as incomplete [9]. Much of the supporting mechanistic detail comes from animal studies [7].
Nothing here is dosing, medical, or safety guidance. Read the studies themselves, including the Expression of Concern, and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 9
- Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity.
- Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
- The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.
- The effect of tesofensine on appetite sensations.
- Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.
- Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.
- Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.
- Expression of concern--Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients.
- Under-reporting of adverse effects of tesofensine.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.